文献速递浆细胞疾病造血干细胞移植与细胞治疗

卡非佐米联合来那度胺地塞米松及移植治疗多发性骨髓瘤的IFM KRd最终结果

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
PubMed 文献 · Blood · 2021-01-01

这项2期研究评估了卡非佐米、来那度胺和地塞米松(KRd)联合移植治疗适合移植的新诊断多发性骨髓瘤患者。46例入组,42例可评估,巩固治疗后 stringent 完全缓解率61.9%,92.6%流式检测MRD阴性。中位随访60.5个月,中位无进展生存56.4个月,无KRd相关死亡,但需监测心血管不良事件。

要点

  • KRd方案8周期联合移植在适合移植的新诊断多发性骨髓瘤中产生快速深度缓解。
  • 巩固治疗后 stringent 完全缓解率61.9%,流式MRD阴性率92.6%。
  • 中位无进展生存56.4个月,无KRd相关死亡,但心血管事件需密切监测。

核心结论

  • 8周期KRd方案在适合移植的新诊断多发性骨髓瘤患者中产生快速且深度的缓解。
  • 安全性可接受,但心血管不良事件应密切监测。

研究设计与样本

  • 这项2期研究纳入46例适合移植的新诊断多发性骨髓瘤患者。
  • 患者接受8个28天周期的KRd方案,第4周期后移植,随后来那度胺维持1年。
  • 主要终点为巩固治疗完成时的 stringent 完全缓解。

主要发现

  • 42例可评估患者中,26例(61.9%)达到 stringent 完全缓解,27例(64.3%)至少达到完全缓解。
  • 92.6%患者流式细胞术检测MRD阴性(≥2.5×10^-5),63.0%患者二代测序检测MRD阴性(10^-6)。
  • 中位达完全缓解时间10.6个月。
  • 中位随访60.5个月,21例进展,10例死亡(其中7例死于多发性骨髓瘤),中位无进展生存56.4个月。

关键数值与推荐

  • KRd方案:卡非佐米20/36 mg/m2(第1-2、8-9、15-16天),来那度胺25 mg(第1-21天),地塞米松20 mg(第1-2、8-9、15-16、22-23天)。
  • 来那度胺维持治疗:10 mg,第1-21天,持续1年。
  • 常见3/4级不良事件:血液学毒性74%,感染22%。
  • 31例患者报告56例严重不良事件,包括8例心血管事件(2例心力衰竭,5例肺栓塞或深静脉血栓)。

临床怎么用

  • 对于适合移植的新诊断多发性骨髓瘤患者,可考虑KRd方案联合移植。
  • 治疗期间应密切监测心血管不良事件。

局限性

  • 本研究为2期单臂研究,样本量较小(46例入组)。
  • 结果需在更大规模随机对照研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase 2 study, patients received eight 28-day cycles of carfilzomib (K) 20/36 mg/m2 (days 1-2, 8-9, 15-16), lenalidomide (R) 25 mg (days 1-21), and dexamethasone (d) 20 mg (days 1-2, 8-9, 15-16, 22-23). All patients proceeded to transplant after 4 cycles and received 1 year of lenalidomide maintenance (10 mg, days 1-21). The primary objective was stringent complete response at the completion of consolidation. Overall, 48 patients were screened and 46 enrolled; 21% had adverse cytogenetics. Among 42 evaluable patients after consolidation, 26 were in stringent complete response (CR; 61.9%), 27 were at least in CR (64.3%): 92.6% had undetectable minimal residual disease according to flow cytometry (≥2.5 × 10-5) and 63.0% according to next-generation sequencing (10-6). Median time to CR was 10.6 months. According to multiparametric flow cytometry and next-generation sequencing, 69.0% and 66.7% of patients, respectively, had undetectable minimal residual disease at some point. With a median follow-up of 60.5 months, 21 patients progressed, and 10 died (7 of multiple myeloma). Median progression-free survival was 56.4 months. There were no KRd-related deaths. Four patients discontinued the program due to toxicities; 56 serious adverse events were reported in 31 patients, including 8 cardiovascular events (2 heart failures, 5 pulmonary embolisms or deep vein thrombosis). Common grade 3/4 adverse events were hematologic (74%) and infectious (22%). In summary, 8 cycles of KRd produce fast and deep responses in transplant-eligible patients with newly diagnosed multiple myeloma. The safety profile is acceptable, but cardiovascular adverse events should be closely monitored. This clinical trial is registered at www.clinicaltrials.gov as #NCT02405364.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Roussel M, Lauwers-Cances V, Wuilleme S, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021. PMID: 33827114. doi:10.1182/blood.2021010744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。